OP0308 Efficacy and safety results of guselkumab in patients with active psoriatic arthritis over 56 weeks from a phase 2a, randomised, double blind, placebo controlled study
Objectives Evaluate efficacy and safety of guselkumab (GUS) in patients (pts) with active psoriatic arthritis (PsA) over 56 weeks (wks) Methods Pts w/active PsA (defined as =3 tender and =3 swollen joints, C reactive protein =3 mg/L) and =3% body surface area (BSA) of plaque psoriasis despite current or previous treatment w/standard of care therapies, including previous TNF inhibitor therapy, were eligible to participate and were randomised 2:1 to receive GUS 100 mg subcutaneously or placebo (PBO) at wk 0, 4, and every 8 wks thereafter through wk44. At wk16, pts from either group with <5% improvement from baseline in both swollen and tender joint counts were eligible for early escape (EE) to open label ustekinumab. All remaining PBO pts crossed over to receive GUS 100 mg at wks24, 28, 36, and 44. At wk56, a post treatment follow up visit was conducted. Efficacy post wk24 through wk44 and wk56 was evaluated in pts who did not EE and continued treatment at wk24 (post wk24 efficacy analysis set) based on observed data. The wk24 data in this population were included as a reference. Results 149 pts were randomised to receive study agent (PBO: 49, GUS: 100) The study met its primary and all secondary endpoints through wk24. At wk24, 29 pts in the PBO group crossed over to receive GUS, of which 28 completed treatment through wk44. 86 pts in the GUS group continued treatment at wk24 and 84 pts completed treatment through wk44. Post wk24, ACR 20/50/70 and PASI 75/90/100 responses improved in PBO to GUS crossover pts and were well maintained in GUS pts through wk44 (last efficacy assessments while on drug) and wk56 (final follow up visit) (table 1) The efficacy results from wk24 through wk44 and wk56 are summarised in table 1. Through wk56, 17.2% of PBO GUS, 46.0% of GUS, and 39.5% of the combined GUS pts had =1 AEs, of which infections and infestations were the most commonly reported (3.4% 27.0% and 21.7% respectively) Post wk24, there was no disproportional increase in overall AE frequency, or infections and infestations among GUS pts with longer exposure. Through wk56, among 129 pts who received GUS, there was 1 pt with malignancy (basal cell carcinoma) 1 pt with 2 serious infections (both pneumonia) 6 pts reported =1 SAEs (myocardial infarction, osteoarthritis, pupils unequal, radius fracture, pneumonia, ulcerative keratitis) 2 pts discontinued treatment due to AEs, 1 pt had neutropenia meeting NCI CTCAE toxicity grade 3, and 6 pts were positive for antibodies to GUS. No deaths occurred through wk56.Abstract OP0308 Table 1 Efficacy results from Wk24 through Wk44 and Wk56 in post Wk24 efficacy analysis set based on the observed data Conclusions In pts with active PsA and =3% BSA of psoriasis, GUS demonstrated substantial benefits on joint symptoms, physical function, psoriasis, enthesitis, dactylitis, and quality of life, and efficacy was well maintained through wk56. GUS was well tolerated with no unexpected safety findings in this population after ~1 year of exposure. Disclosure of Interest A. Deodhar Grant/research support from: Janssen Research and Development, LLC, A. Gottlieb Grant/research support from: Janssen Research and Development, LLC, W. H. Boehncke Grant/research support from: Janssen Research and Development, LLC, B. Dong Shareholder of: Johnson and Johnson, LLC, Employee of: Janssen Research and Development, LLC, Y. Wang Shareholder of: Johnson and Johnson, LLC, Employee of: Janssen Research and Development, LLC, Y. Zhuang Shareholder of: Johnson and Johnson, LLC, Employee of: Janssen Research and Development, LLC, W. Barchuk Shareholder of: Johnson and Johnson, LLC, Employee of: Janssen Research and Development, LLC, X. Xu Shareholder of: Johnson and Johnson, LLC, Employee of: Janssen Research and Development, LLC, E. Hsia Shareholder of: Johnson and Johnson, LLC, Employee of: Janssen Research and Development, LLC